|
gptkbp:instanceOf
|
antiviral drug
investigational drug
|
|
gptkbp:administeredBy
|
gptkb:tablet
capsule
mild to moderate COVID-19
|
|
gptkbp:alternativeName
|
gptkb:molnupiravir
gptkb:EIDD-2801
|
|
gptkbp:approvedBy
|
gptkb:Japan
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:brand
|
gptkb:Lagevrio
|
|
gptkbp:CASNumber
|
2349386-89-4
|
|
gptkbp:chemicalClass
|
antiviral drug
|
|
gptkbp:contraindication
|
pregnancy
|
|
gptkbp:developedBy
|
gptkb:Merck_&_Co.
gptkb:Ridgeback_Biotherapeutics
|
|
gptkbp:discoveredIn
|
gptkb:Emory_University
|
|
gptkbp:firstDescribed
|
2019
|
|
gptkbp:hasMolecularFormula
|
C13H19N3O7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
MK-4482
|
|
gptkbp:mechanismOfAction
|
RNA polymerase inhibitor
|
|
gptkbp:patent
|
gptkb:Emory_University
gptkb:Merck_&_Co.
|
|
gptkbp:prodrugOf
|
gptkb:N4-hydroxycytidine
|
|
gptkbp:regulates
|
gptkb:FDA
gptkb:MHRA
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
dizziness
headache
|
|
gptkbp:status
|
approved in some countries
under clinical trials
|
|
gptkbp:target
|
gptkb:COVID-19
gptkb:influenza_virus
other RNA viruses
|
|
gptkbp:usedFor
|
gptkb:COVID-19
|
|
gptkbp:bfsParent
|
gptkb:Molnupiravir
|
|
gptkbp:bfsLayer
|
6
|